This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Sarcoidosis of other and combined sites / Multisystem sarcoidosis / Extrapulmonary sarcoidosis기타 및 복합부위의 사르코이드증 (폐외·다장기 사르코이드증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D86.8 (Sarcoidosis of other and combined sites) | Related additional codes: sarcoid arthropathy M14.8*, sarcoid myocarditis I41.8*, sarcoid myositis M63.3*, iridocyclitis in sarcoidosis H22.1*, multiple cranial nerve palsies in sarcoidosis G53.2* | Special Copayment Reduction: V111 (rare disease)
B. SynonymsSarcoidosis of other and combined sites, sarcoid arthropathy (M14.8*), sarcoid myocarditis (I41.8*), sarcoid myositis (M63.3*), uveoparotid fever (Heerfordt syndrome), iridocyclitis in sarcoidosis (H22.1*), multiple cranial nerve palsies in sarcoidosis (G53.2*), extrapulmonary sarcoidosis, systemic sarcoidosis, Multisystem sarcoidosis, Extrapulmonary sarcoidosis
C. Adult onsetAdult onset common — develops mainly in adults in their 20s–40s and after 50; a multi-organ disease accompanied by involvement of organs outside the lungs (heart, eyes, skin, nervous system, musculoskeletal system, liver, kidneys, etc.). Some cases present with extrapulmonary symptoms from the start and are diagnosed as a rare systemic disease.
1. History1877 Jonathan Hutchinson describes skin lesions → 1899 Caesar Boeck coins the name "sarcoid" → 1914 Heerfordt describes uveoparotid fever → 1940s–60s the pattern of systemic involvement is systematized → 1999 ATS/ERS/WASOG international guideline → the modern concept of multisystem sarcoidosis is established.
2. CausesExcessive granulomatous response of a genetically predisposed host to environmental antigens (organic dust, mycobacteria, Propionibacterium species, etc.). Strongly associated with HLA-DRB1 alleles. Occupational (firefighters, metalworkers) and regional (rural environment) risk factors exist.
3. GeneticsHLA-DRB1*03:01, DRB1*11, DRB1*12 susceptibility alleles; many susceptibility genes including BTNL2 (butyrophilin-like 2), ANXA11, and RAB23. Familial occurrence 4–17%. Genotype-phenotype associations differ by ethnicity: in Black patients DRB1*15:01 is associated with cardiac sarcoidosis.
4. General epidemiologyWorldwide prevalence 10–40/100,000. High in Northern Europe and among African Americans (60–80/100,000). Incidence in Korea is low but gradually increasing; the proportion of cardiac sarcoidosis is relatively higher in Japan and Korea than in the West. Slight female predominance; bimodal age distribution of onset in the 20s–40s and after 50.
5. PathophysiologyAntigen-presenting cells (dendritic cells, macrophages) → T helper 1 (Th1)-skewed immune response → overproduction of IFN-γ and TNF-α → macrophage activation → non-caseating granuloma formation → target organ involvement. Imbalance between CD4+ T cells and regulatory T cells, and cell recruitment by chemokines such as CCL2 and CXCL10, determine multi-organ involvement.
6. SymptomsSystemic symptoms such as fatigue, fever, and weight loss; palpitations and syncope (heart); decreased vision and uveitis (eyes); facial nerve palsy and headache (nervous system); arthralgia and myalgia (musculoskeletal system); skin nodules and erythema (skin); abdominal pain and hepatosplenomegaly (liver and spleen); polyuria and diabetes insipidus (kidney and pituitary).
7. SignsFacial nerve palsy (Bell palsy), uveitis findings, cutaneous sarcoid (sarcoid plaque/nodule), erythema nodosum, electrocardiogram abnormalities (AV block, bundle branch block), hepatosplenomegaly, lymphadenopathy (hilar and peripheral), hypercalcemia, elevated serum ACE.
8. ScreeningSerum ACE, serum calcium, LDH, 24-hour urinary calcium; chest X-ray (hilar lymphadenopathy, evaluation of pulmonary infiltrates); electrocardiogram (screening for cardiac involvement); ophthalmologic slit-lamp examination (screening for uveitis); MRI if cranial nerve abnormality; clinical diagnosis of Löfgren syndrome.
9. DiagnosisHistopathologic confirmation of non-caseating granuloma (skin, lymph node, bronchial biopsy) is the standard. Heart: CMR (contrast-enhanced LGE pattern) + FDG-PET; nervous system: MRI + CSF analysis; eyes: slit lamp + FA + OCT. Differential diagnosis from tuberculosis, fungal infection, foreign body granuloma, etc. is essential. Confirm HES (Histiocytes, Eosinophils, Schaumann bodies) histologic findings.
10. TreatmentCorticosteroids (prednisolone 0.5–1 mg/kg/day) are first-line treatment; methotrexate, azathioprine, and leflunomide as steroid-sparing agents; ICD implantation in cardiac sarcoidosis, MTX + steroid combination in neurosarcoidosis; infliximab and adalimumab (refractory cases).
11. PrognosisSpontaneous remission in 2/3. Poor prognosis with cardiac or neurologic involvement (heart: risk of sudden death; nervous system: permanent disability). Löfgren syndrome is favorable. In the chronic progressive form (10–30%), irreversible organ damage such as pulmonary fibrosis, heart failure, and vision loss. 5-year mortality about 1–5%, but up to 10% in cardiac sarcoidosis.
12. PreventionPrimary prevention unclear (pathogenesis unclear). Secondary prevention: early diagnosis and treatment, prophylactic ICD implantation in cardiac sarcoidosis, regular eye examinations, prevention of steroid side effects (bisphosphonates, blood glucose monitoring). Tertiary prevention: monitoring for relapse, rehabilitation, improvement of the occupational environment.
13. ReferencesHunninghake GW et al. ATS/ERS/WASOG Statement on Sarcoidosis (1999) and 9 other major papers

1. History

The history of sarcoidosis begins in European dermatology in the late 19th century. In 1877, the British dermatologist Jonathan Hutchinson described in a British dermatology journal the case of a patient with unusual purple patches on the hands and feet, and named it "Mortimer's malady." This report is now recognized as the first systematic description of skin involvement in sarcoidosis. In 1889, the Norwegian physician Caesar Boeck observed that similar skin lesions appeared as intradermal nodules and, because the histologic features of these lesions resembled sarcoma, introduced the term "sarkoid" (Greek sarx = flesh, eidos = resembling) (1899). Subsequently, the Swedish ophthalmologist and otolaryngologist Christian Friis Heerfordt described in 1909 the syndrome known as "uveoparotid fever," a characteristic syndrome consisting of uveitis, parotid gland enlargement, facial nerve palsy, and fever, now called Heerfordt syndrome or uveoparotid fever and classified as one of the typical presentations of neurosarcoidosis.

In 1914, the German pathologist Jörgen Nicolai Schaumann systematically reported that identical granulomatous lesions were found in various organs such as the lungs, lymph nodes, skin, liver, and spleen, and was the first to understand this as the multi-organ expression of a single systemic disease. He described the characteristic calcified inclusion bodies within granulomas (Schaumann bodies), which are now named after him as one of the histopathologic findings of sarcoidosis. In the 1940s–50s, Reed B. Carmichael and others in the United States attempted a radiologic staging classification of thoracic sarcoidosis, and the efficacy of corticosteroids in treating sarcoidosis was first reported.

After the mid-20th century, as it became established that sarcoidosis can involve virtually any organ outside the lungs, including the heart, eyes, nervous system, skin, musculoskeletal system, and kidneys, the concepts of "extrapulmonary sarcoidosis" and "multisystem sarcoidosis" emerged. In 1966, Siltzbach et al. summarized the various patterns of organ involvement in sarcoidosis through a large clinical study involving 11 centers worldwide, and reported that cardiac sarcoidosis occurs at a high rate particularly in Japan and among Black people. In 1999, the American Thoracic Society (ATS), European Respiratory Society (ERS), and World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) jointly published international diagnostic and treatment guidelines for sarcoidosis, which remain the foundation guidelines for sarcoidosis management to this day. The 2022 revision of the European Respiratory Society (ERS) guidelines systematized the use of the latest imaging techniques, including FDG-PET/CT and cardiac MRI, and the evaluation of multi-organ involvement.

In Korea, sarcoidosis was relatively rare, but reports are increasing with advances in diagnostic techniques and greater awareness. In particular, in Korea, cardiac sarcoidosis tends to be found at a relatively higher rate than pulmonary sarcoidosis, so the differential diagnosis of sarcoidosis is gaining importance in patients with unexplained ventricular arrhythmia, atrioventricular block, or non-ischemic cardiomyopathy.


2. Causes

The exact cause of sarcoidosis has not yet been fully elucidated, but it is currently understood that an abnormal immune response (excessive granulomatous response) to specific environmental antigens occurs in a genetically susceptible host. It is a multifactorial disease in which many environmental and genetic factors interact in a complex way rather than a single cause.

Environmental factors

Various occupational and environmental exposures are associated with the development of sarcoidosis. The strongest environmental associated factor is organic antigens; cell wall components of bacteria such as mycobacteria (Mycobacterium tuberculosis, M. paratuberculosis), Propionibacterium acnes, and rickettsiae have been repeatedly detected within sarcoidosis granulomas. This suggests that sarcoidosis may be triggered by an atypical immune response to these microorganisms. However, because the microorganisms themselves cannot be cultured, mechanisms of "molecular mimicry" or "antigen persistence" due to microbial antigen components, rather than a fully infectious origin, have been proposed.

Occupational risk factors include firefighters, metal dust (excluding beryllium), pesticides, and mold making, and it has been reported that the incidence of sarcoidosis was significantly higher than in the general population in the cohort of US 9/11 terror site recovery workers. Rural residence, bird droppings, and building material dust are also reported to be associated. Conversely, smoking is known to paradoxically lower the risk of sarcoidosis, and a mechanism in which smoking partly suppresses hyperactive alveolar macrophages has been proposed.

Infection-related hypothesis

Catalytic antigen (catalase-peroxidase, mKatG) of Mycobacterium tuberculosis and the ESAT-6 protein are detected at a high frequency in the bronchoalveolar lavage fluid and serum of sarcoidosis patients. Propionibacterium acnes has been repeatedly identified within granulomas of Japanese sarcoidosis patients in particular, and Japanese researchers strongly support it as a candidate cause. The currently dominant hypothesis is that antigen components of these microorganisms are presented to CD4+ T cells by HLA-II molecules, triggering a Th1-skewed response.

Non-infectious environmental factors

Chronic beryllium disease (CBD) caused by beryllium exposure is histologically indistinguishable from sarcoidosis, and it has been shown that in carriers of the HLA-DP*02:01 allele, beryllium antigen triggers the same granuloma-forming mechanism. The pathophysiologic similarity between CBD and sarcoidosis strongly suggests that specific antigens also act by a similar mechanism in sarcoidosis.


3. Genetics

Sarcoidosis is not a simple single-gene disease but a complex genetic disease with polygenic susceptibility. The frequency of familial occurrence is about 4–17%, and the concordance rate in monozygotic twins is significantly higher than in dizygotic twins, showing that a genetic component definitely exists.

HLA genes

The strongest contribution to genetic susceptibility to sarcoidosis comes from human leukocyte antigen (HLA) genes, particularly HLA class II genes. HLA-DRB1*03:01 (also called DRB1*0301) is a strong susceptibility allele for Löfgren syndrome (acute sarcoidosis) in Europeans and Scandinavians and is associated with a benign prognosis. In contrast, HLA-DRB1*15:01 is associated with cardiac sarcoidosis in Black Americans and with a chronic course with poor prognosis. HLA-DRB1*11 and DRB1*12 are reported to increase susceptibility in various populations. Because HLA molecules play a role in the antigen presentation process of presenting peptides of specific sarcoidosis-triggering antigens (e.g., mKatG) to CD4+ T cells, HLA polymorphism plays a central role in determining the initiation of sarcoidosis and the pattern of organ involvement.

Non-HLA susceptibility genes

Many non-HLA susceptibility genes have been identified through genome-wide association studies (GWAS). Loss-of-function variants of BTNL2 (butyrophilin-like 2, 6p21.3) increase sarcoidosis susceptibility in both Europeans and Japanese, and BTNL2 is presumed to act as an inhibitory regulator of T-cell activation, so loss of this function leads to an excessive immune response. Variants of ANXA11 (annexin A11) (R230C) increase susceptibility in association with abnormal function of the calcium-binding protein. RAB23 is a vesicle transport regulatory protein associated with granuloma-formation signaling. Variants in immune regulatory genes such as TNFA (TNF-α), IL23R, IL12B, and TYK2 are also reported to influence sarcoidosis susceptibility and clinical course.

Genotype-phenotype associations by race and ethnicity

The association between genotype and phenotype differs by race and ethnicity. In Scandinavians, carriers of HLA-DRB1*03:01 present with Löfgren syndrome (acute erythema nodosum, bilateral hilar lymphadenopathy, arthritis, fever) and have a high spontaneous remission rate. In African Americans, more severe multi-organ involvement, a chronic course, and cardiac and neurologic involvement are frequent, and the proportion carrying HLA-DRB1*15:01 is high. In East Asians, including Japanese and Koreans, the proportion of cardiac sarcoidosis is relatively high, and the hypothesis that P. acnes-related gene variants contribute to granuloma formation is supported.


4. General epidemiology

Sarcoidosis is a systemic granulomatous disease distributed worldwide, but prevalence and clinical features differ markedly by geography, race, and sex. Worldwide prevalence is estimated at 10–40 per 100,000 population, and incidence varies widely by region at 1–40 per 100,000 per year.

Prevalence by region

The highest incidence (40–80 per 100,000) is reported in Northern Europe (Sweden, Norway, Denmark) and Iceland. In the United States, African Americans (35–80 per 100,000) have an incidence 3–5 times higher than white Americans (10–12 per 100,000), and the clinical course also tends to be more severe. Relatively low prevalence is reported in Asia and Africa, but this may be an underestimate reflecting differences in access to diagnosis. Japan is the country in Asia with the most accumulated sarcoidosis data; the annual incidence is estimated at about 1–3 per 100,000, and the proportion of extrapulmonary involvement, particularly cardiac sarcoidosis, is relatively higher than in the West.

Epidemiology in Korea

Precise epidemiologic data on sarcoidosis in Korea are limited. Studies using National Health Insurance claims data observe a gradually increasing trend in prevalence and incidence, which is interpreted as the combined result of a true increase in occurrence and improved diagnosis rates. Cardiac sarcoidosis is also reported at a relatively high rate in Korea, reflecting an East Asian genetic background similar to Japan. Pulmonary sarcoidosis is the most common form, but the proportion of cases first diagnosed through extrapulmonary and multi-organ involvement is also not small. In patients with cardiac sarcoidosis, first presentation with unexplained complete atrioventricular block or ventricular tachycardia is frequent, and greater awareness is needed in cardiology and arrhythmia specialty centers.

Sex and age distribution

Worldwide, incidence is slightly higher in women, and the age distribution of onset is bimodal. The first peak of onset is in the 20s to early 40s, and the second peak is in the mid-50s to 60s, particularly evident in women. Onset in children is rare, and cases occurring in infants under 5 years of age are classified as a special form (early-onset sarcoidosis, requiring differentiation from Blau syndrome).


5. Pathophysiology

The core pathophysiology of sarcoidosis is the formation of non-caseating epithelioid granulomas, which is the result of an excessive, dysregulated cell-mediated immune response to environmental antigens.

Antigen presentation and T-cell activation

Environmental antigens (sarcoidosis-triggering antigens) that enter by inhalation (mainly the lungs) or other routes are phagocytosed and processed by alveolar macrophages and dendritic cells and then presented to CD4+ T lymphocytes through HLA class II molecules (mainly DR molecules). In this process, recognition of the antigen-HLA complex by the T-cell receptor (TCR) takes place, and T-cell activation is initiated together with costimulatory signals (B7-CD28, etc.).

Th1-skewed cytokine environment

Activated T cells differentiate into the Th1 (T helper 1) lineage and produce large amounts of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). IFN-γ converts macrophages to an M1-type activated state, causing them to additionally secrete IL-12, TNF-α, IL-1β, and others, thereby forming a positive feedback loop. TNF-α plays a key role in maintaining granulomas and in the differentiation of macrophages into epithelioid cells. This cytokine environment also attracts additional T cells and macrophages to the lesion via CXCL10 (IP-10), and CCL2 (MCP-1) continuously recruits monocytes and macrophages, expanding and maintaining the granuloma.

Granuloma formation and maintenance

Epithelioid macrophages aggregate and form multinucleated giant cells, located in the center. These are surrounded by CD4+ T cells, fibroblasts, mast cells, and others, completing the granuloma structure. Reduced suppressive function of CD4+CD25+FOXP3+ regulatory T cells (Tregs) is thought to play an important role in this process. If normal regulatory T cells function sufficiently, the granulomatous response is limited and spontaneous remission occurs, but if regulatory function fails or the antigen persists, the granuloma becomes chronic.

Determinants of multi-organ involvement

The determining mechanism by which sarcoidosis involves a particular organ has not been fully elucidated. However, it is reported that the expression pattern of chemokine receptors (CXCR3, CCR2, etc.), T-cell clonotype (TCR Vβ usage pattern), and specific HLA genotypes are related to organ-specific involvement patterns (e.g., the association of HLA-DRB1*15:01 with cardiac involvement). In cardiac sarcoidosis, granulomas form centered on the myocardial interstitium and conduction system, causing atrioventricular block, ventricular arrhythmia, and decreased systolic function. In neurosarcoidosis, granulomas form in the meninges, cranial nerves, brain parenchyma, and spinal cord, causing various neurologic symptoms.

Transition to fibrosis

In the final stage of chronic granulomatous inflammation, fibroblast activation due to overproduction of TGF-β (transforming growth factor-β) occurs, and progressive fibrosis develops around the granulomas. This fibrotic process leads to pulmonary fibrosis in the lungs, myocardial fibrosis and functional decline in the heart, and irreversible visual impairment in the eyes, and is the main cause of irreversible organ damage for which full recovery is impossible despite treatment.


6. Symptoms

Sarcoidosis of other and combined sites (D86.8) is a form involving multiple organs outside the lungs or together with the lungs, and shows a very wide spectrum of symptoms depending on the organs involved. Systemic symptoms appear in combination with organ-specific symptoms.

Systemic symptoms

In about 1/3 of sarcoidosis patients, nonspecific systemic symptoms such as fatigue, low-grade fever, weight loss, and night sweats occur. Fatigue does not necessarily correlate with disease activity, often persists even after treatment, and greatly affects patients' quality of life. Löfgren syndrome is an acute presentation characterized by the tetrad of bilateral hilar lymphadenopathy, erythema nodosum, ankle arthritis, and fever; it occurs mainly in young women of European descent, and most cases remit spontaneously within 2 years.

Cardiac sarcoidosis symptoms

Cardiac sarcoidosis presents clinically in 5–10% of all sarcoidosis (Western figures), but when cardiac tissue is examined directly, granulomas are found in 25% or more. The main symptoms are palpitation, syncope, presyncope, dyspnea, and chest pain. Sudden cardiac death (SCD) can be the first manifestation, making it the clinically most dangerous form of presentation. Atrioventricular block (AV block), ventricular tachycardia, and ventricular fibrillation are characteristic arrhythmias. In advanced cases, heart failure with a dilated cardiomyopathy pattern occurs. In Japan and Korea, sarcoidosis is considered an important differential diagnosis in adult patients with unexplained complete atrioventricular block.

Ocular sarcoidosis symptoms

Eye involvement occurs in 20–50% of all sarcoidosis and is one of the most common forms of extrapulmonary involvement. Uveitis, especially anterior uveitis, is the most common, with red eyes, photophobia, decreased vision, and floaters. Posterior uveitis and panuveitis carry a greater risk of visual impairment. Yellow nodules on the conjunctiva (conjunctival granuloma) may be observed, and this is a favorable access site for tissue diagnosis by biopsy. In Heerfordt syndrome, parotid enlargement and facial nerve palsy accompany uveitis. Optic nerve involvement (optic neuritis) is rare but can cause sudden vision loss.

Neurosarcoidosis symptoms

Nervous system involvement occurs in 5–15% of all sarcoidosis and can leave serious neurologic disability. Facial nerve palsy (Bell palsy) is the most common neurologic manifestation, and multiple cranial nerve palsies (multiple cranial neuropathy) are characteristic. Headache, meningitis, hydrocephalus, cognitive decline, and epileptic seizures may occur. With pituitary involvement, diabetes insipidus, hyperprolactinemia, and hypothalamic dysfunction occur. With spinal cord involvement, lower limb paralysis, sensory abnormalities, and bladder dysfunction occur, and peripheral neuropathy may present as sensory abnormalities and small fiber neuropathy. Chronic granulomatous meningitis due to meningeal involvement follows a subacute or chronic course, and diagnosis is often delayed.

Musculoskeletal symptoms

Joint involvement occurs in 15–25% of all sarcoidosis. Sarcoid arthropathy (ICD-10 M14.8*) presents as arthralgia and joint swelling in large joints (ankles, knees, wrists, elbows), and when associated with Löfgren syndrome, spontaneous remission is common. Chronic arthritis is rare but can lead to erosive joint destruction. Bone sarcoidosis presents as cystic lesions in the phalanges of the hands and feet, with characteristic radiographic findings. Sarcoid myopathy (M63.3*) is mostly asymptomatic but may present as proximal muscle weakness, myalgia, and muscle stiffness, and is rarely palpable as an isolated mass (sarcoid nodular myopathy).


7. Signs

The main physical examination signs and laboratory abnormalities seen in sarcoidosis of other and combined sites are as follows.

Skin signs

Erythema nodosum is a tender red subcutaneous nodule occurring on the front of the lower legs, is a component of Löfgren syndrome, and is associated with a benign prognosis. Lupus pernio is an indurated blue-purple macule or papule occurring on the face, nose, and ears, and is a specific skin manifestation suggesting chronic sarcoidosis and upper respiratory tract involvement. Sarcoid skin involvement in plaque or nodular form may be observed, and in scar sarcoidosis, granulomas infiltrate old surgical scars, so that the scar turns magenta and protrudes.

Cardiac signs

On physical examination, an irregular pulse (in arrhythmia), bradycardia (in complete atrioventricular block), crackles (in heart failure), and a third heart sound (in heart failure) may be heard on auscultation. On electrocardiography, AV block (especially second- or third-degree), bundle branch block, ventricular premature contractions, and ventricular tachycardia are observed. Echocardiography may show regional wall motion abnormalities, a dilated cardiomyopathy pattern, decreased ventricular function, and pericardial effusion.

Ophthalmic signs

On slit-lamp examination, keratic precipitates (KPs), vitreous cells, and aqueous flare, which are signs of anterior uveitis, are observed. Yellow-white conjunctival nodules, retinal periphlebitis, retinal vascular lesions with a candle wax dripping appearance, and papilledema may appear. Parotid enlargement (Heerfordt syndrome) may be observed bilaterally.

Neurological signs

Facial nerve palsy (unilateral or bilateral peripheral facial palsy), multiple cranial nerve palsies (oculomotor, abducens, vestibulocochlear nerves, etc.), signs of meningeal irritation, optic disc edema, cerebellar ataxia, and signs of myelopathy (decreased muscle strength, reflex abnormalities, Babinski sign) may appear.

Laboratory abnormalities

Elevated serum angiotensin-converting enzyme (ACE) occurs in 50–70% of active sarcoidosis but has low specificity. Elevated serum calcium (hypercalcemia) occurs in 10–20% of active sarcoidosis and results from the increased capacity of activated macrophages to convert 25-OH vitamin D to 1,25-OH vitamin D (calcitriol). Elevated LDH, increased ESR, and decreased albumin may also be observed.


8. Screening

Systematic screening for sarcoidosis, especially the extrapulmonary multi-organ form, is important for early diagnosis and prevention of serious complications. A screening approach is needed to evaluate multi-organ involvement when sarcoidosis is suspected or in patients already diagnosed with pulmonary sarcoidosis.

Basic laboratory tests

In all patients, perform serum ACE, serum calcium (total and ionized), 24-hour urinary calcium, CBC (complete blood count), ESR, CRP, LFT (liver function tests), and renal function tests (BUN/Cr). Elevated ACE is a marker of active sarcoidosis and is also used to track treatment response. Hypercalcemia suggests a risk of kidney stones and renal failure. Measuring 1,25-OH vitamin D is also useful.

Cardiac screening

A 12-lead electrocardiogram (ECG) is recommended in all sarcoidosis patients. If the ECG shows abnormalities such as AV block, bundle branch block, or ventricular premature contractions, cardiac magnetic resonance imaging (CMR) and FDG-PET/CT (18F-fluorodeoxyglucose positron emission tomography) are added. 48-hour Holter monitoring is useful for detecting intermittent arrhythmia. Echocardiography is the basis of cardiac function assessment and confirms decreased ventricular function, regional wall motion abnormalities, and pericardial effusion. On CMR, a septal patchy pattern of late gadolinium enhancement (LGE) or a subepicardial/intramyocardial non-ischemic pattern is characteristic of cardiac sarcoidosis.

Ophthalmologic screening

In all sarcoidosis patients, even without symptoms, perform slit-lamp examination and fundus examination. Uveitis, keratic precipitates, and conjunctival nodules are screened for. If there are red eyes, photophobia, decreased vision, or floaters, fluorescein angiography (FA) and optical coherence tomography (OCT) are added.

Neurologic screening

If there are neurologic symptoms such as headache, cranial nerve palsy, cognitive abnormality, or syncope, perform brain MRI (contrast-enhanced). Meningeal involvement, brain parenchymal granuloma, pituitary involvement, and white matter lesions are identified. If needed, perform cerebrospinal fluid (CSF) analysis (cell count, protein, glucose, ACE, ADA, etc.).

Musculoskeletal screening

If there is arthralgia or myalgia, joint X-ray, ultrasound, and MRI are used. Muscle enzymes (CK, LDH, aldolase) are measured to screen for myositis. FDG-PET/CT is useful for simultaneously evaluating whole-body sites of inflammation and organs involved.


9. Diagnosis

In principle, the diagnosis of sarcoidosis requires fulfilling three elements: (1) clinical and radiologic evidence, (2) confirmation of non-caseating granuloma on histopathology, and (3) exclusion of other causes that can produce the same lesions. The 2022 ERS guideline retained these three requirements while expanding the role of imaging techniques.

Histopathologic diagnosis

The gold standard of diagnosis is histopathologic confirmation of non-caseating epithelioid granuloma. The granuloma consists of epithelioid histiocytes, multinucleated giant cells (Langhans-type or foreign body-type), and lymphocytes, and the absence of central caseating necrosis is the key distinguishing finding from tuberculosis. However, a small amount of fibrinoid necrosis may rarely appear in sarcoidosis tissue as well. Characteristic inclusion bodies include Schaumann bodies (laminated calcified inclusion bodies) and asteroid bodies (radial inclusion bodies), which are observed more commonly in sarcoidosis but are not disease-specific. AFB smear/culture and fungal culture tests are performed on tissue specimens at the same time to exclude infectious granulomas.

Selection of biopsy site

Select the safest and easiest biopsy site first. Skin lesions (lupus pernio, subcutaneous nodules, scar sarcoidosis) are the easiest to access and have a high diagnostic yield. Conjunctival nodules can be easily biopsied through ophthalmology consultation. Bronchial mucosal biopsy, bronchoalveolar lavage (BAL), transbronchial lung biopsy (TBLB), and endobronchial ultrasound (EBUS)-guided fine-needle aspiration (FNA) via bronchoscopy are the standard diagnostic methods for pulmonary and hilar sarcoidosis. EBUS-FNA has a diagnostic sensitivity of 80–90% for hilar and mediastinal lymph nodes. Peripheral lymph node biopsy, liver biopsy, and muscle biopsy are also performed depending on the situation.

Diagnosis of cardiac sarcoidosis

The sensitivity of cardiac tissue biopsy (endomyocardial biopsy) is low at 20–30%, so it is difficult to rely on it alone. Therefore, according to the 2014 HRS (Heart Rhythm Society) expert consensus statement and the 2022 JCS (Japanese Circulation Society) guideline, noninvasive imaging criteria are important. LGE with a non-ischemic pattern on CMR and focally increased myocardial metabolism on FDG-PET/CT are the key imaging findings, and cardiac sarcoidosis can be diagnosed by combining them with tissue diagnosis of extrapulmonary sarcoidosis. The JCS criteria allow a "probable" diagnosis of cardiac sarcoidosis from clinical and imaging findings without tissue diagnosis.

Diagnosis of neurosarcoidosis

For the diagnosis of neurosarcoidosis, clinical symptoms, MRI findings (leptomeningeal enhancement, brain parenchymal lesions, pituitary involvement, spinal cord lesions), and CSF analysis (lymphocyte-predominant pleocytosis, elevated protein, decreased or normal glucose, elevated CSF-ACE) are used. When tissue diagnosis is difficult, confirmation of sarcoidosis in other organs and clinical diagnosis by exclusion are combined. The 2018 criteria of the Neurosarcoidosis Consortium Consensus Group are widely referenced.

Differential diagnosis

Differentiation is needed from tuberculosis (Mycobacterium tuberculosis culture/PCR, TST, IGRA), nontuberculous mycobacterial infection, fungal infection (cryptococcosis, histoplasmosis), chronic beryllium disease (occupational history + BeIT/BeLPT tests), extrinsic allergic alveolitis (hypersensitivity pneumonitis, IgE and specific antigen antibody tests), granulomatosis with polyangiitis (GPA, ANCA test), foreign body granuloma (occupational history), EBV/CMV infection, lymphoma (PET + histopathology), and others.


10. Treatment

The goals of sarcoidosis treatment are symptom control, preservation of organ function, and prevention of irreversible organ damage. Not all sarcoidosis requires treatment, and mild or asymptomatic cases can be observed. However, when there is life- or function-threatening organ involvement such as the heart, nervous system, eyes, or kidneys, active treatment is necessary.

Corticosteroids (first-line treatment)

Prednisolone is the standard first-line treatment for sarcoidosis. The initial dose varies with the organ involved and severity, but it is generally started at 0.5–1 mg/kg/day (usually 20–40 mg/day), the response is assessed after 4–6 weeks, and the dose is gradually tapered. The maintenance dose is 5–10 mg/day, maintained for at least 12–24 months before attempting discontinuation. In cardiac sarcoidosis, treatment starts at an initial 40–60 mg/day, and in neurosarcoidosis a high dose of 1 mg/kg/day (maximum 60–80 mg/day) is recommended. For anterior uveitis in ocular sarcoidosis, treatment begins with steroid eye drops and mydriatics, and systemic steroids are given for posterior involvement or if refractory to eye drops.

Steroid-sparing agents (second-line treatment)

When there are steroid side effects, steroid dependence, or insufficient response, methotrexate (MTX), azathioprine, leflunomide, and hydroxychloroquine are added or used as steroid substitutes. MTX (oral 10–15 mg/week) is the most widely used steroid-sparing agent in pulmonary, skin, and neurologic sarcoidosis. Concomitant folic acid is essential, and monitoring for liver toxicity is needed. Hydroxychloroquine is especially effective for skin and joint involvement and hypercalcemia.

Biologics (treatment for refractory disease)

When refractory to steroids and steroid-sparing agents, TNF-α inhibitors are used. Infliximab (3–5 mg/kg IV, at 0, 2, and 6 weeks and then every 8 weeks) has the most evidence, and efficacy has been reported in refractory pulmonary, neurologic, cardiac, and skin sarcoidosis. Adalimumab is also used on similar evidence. Etanercept has not been shown to be effective in sarcoidosis and is not recommended. Screening and treatment for latent tuberculosis infection (LTBI) before administering biologics is essential.

Treatment specific to cardiac sarcoidosis

In cardiac sarcoidosis, treatment of arrhythmia and heart failure is combined with steroid treatment. Insertion of an implantable cardioverter-defibrillator (ICD) is strongly recommended when there is sustained ventricular tachycardia, complete atrioventricular block, or decreased cardiac function (LVEF < 35%). The ICD plays a key role in preventing sudden cardiac death in sarcoidosis. Electrophysiologic treatment of ventricular tachycardia (catheter ablation) may also be performed in recurrent ventricular tachycardia, but the risk of recurrence is high because of extensive fibrosis within the heart. In advanced heart failure, heart transplantation is considered as the final treatment.

Treatment of neurosarcoidosis

Neurosarcoidosis is started with high-dose steroids (prednisolone 1 mg/kg/day), and in cases refractory to steroids or chronic and relapsing, MTX, mycophenolate mofetil (MMF), or infliximab is added. When intracranial pressure is elevated, acetazolamide and ventriculoperitoneal shunt (VP shunt) are considered.


11. Prognosis

The prognosis of sarcoidosis varies greatly with the organ involved, the clinical presentation, race and ethnicity, and genotype. Overall, in about 2/3 of patients spontaneous remission or remission after treatment response occurs, but 1/3 follow a chronic progressive course.

General prognosis

The 5-year mortality of sarcoidosis overall is relatively low at about 1–5%, but it is higher when cardiac sarcoidosis is included. Spontaneous remission is most common in acute presentations (Löfgren syndrome, acute uveitis, etc.), with remission in 90% or more within 2–5 years. In the chronic progressive form, irreversible organ damage such as pulmonary fibrosis, heart failure, vision loss, and renal failure may occur.

Prognosis of cardiac sarcoidosis

Cardiac sarcoidosis is the most important cause of sarcoidosis-related death. Patients with untreated cardiac sarcoidosis have a high risk of sudden cardiac death and a poor 5–10-year prognosis. Combining ICD implantation with steroid treatment improves survival. The wider the extent of LGE on CMR and the greater the extent of active inflammation on FDG-PET, the worse the prognosis. Decreased LVEF (< 35%) is a strong risk factor for progression of heart failure and death.

Prognosis of neurosarcoidosis

Complete remission after treatment occurs in 30–40% of neurosarcoidosis, but 50–60% show relapse or a chronic course, and 10–20% are left with permanent neurologic disability. Early diagnosis and aggressive immunosuppressive treatment are the key factors improving prognosis. The prognosis is worse when there is brain parenchymal involvement, multiple cranial nerve palsies, or spinal cord involvement.

Prognosis of ocular sarcoidosis

Acute anterior uveitis mostly responds well to treatment, but recurrence is common. In chronic uveitis, posterior uveitis, and panuveitis, the risk of visual impairment from cataract, glaucoma, macular edema, and retinal complications increases. Early diagnosis and ophthalmologic follow-up are essential for preserving vision.


12. Prevention

Because the cause of sarcoidosis has not been fully elucidated, primary prevention is difficult. However, secondary and tertiary prevention strategies that prevent disease progression, complications, and organ damage are important.

Primary prevention (avoiding risk factors)

No causal relationship allowing complete prevention has been established, but wearing respiratory protection and minimizing dust exposure in occupational risk groups (firefighters, metalworkers, agricultural workers) are reasonable preventive measures. In beryllium-exposed workers, appropriate environmental management and biological monitoring (BeIT test) are recommended to prevent chronic beryllium disease (a sarcoidosis-like disease). Wearing appropriate personal protective equipment against organic dust, dust, and building material dust also applies.

Secondary prevention (early diagnosis and prevention of complications)

Prevention of cardiac complications: electrocardiogram in all patients at diagnosis of sarcoidosis, early evaluation of cardiac involvement by CMR + FDG-PET/CT if the ECG is abnormal, consideration of prophylactic ICD implantation in the high-risk group for ventricular arrhythmia. Prevention of ophthalmologic complications: early detection of uveitis and treatment initiation through regular ophthalmologic examinations, monitoring of intraocular pressure and cataract during long-term steroid use. Prevention of metabolic complications: monitoring for hypercalcemia, limiting excessive calcium and vitamin D intake, adequate fluid intake (prevention of kidney stones). Prevention of steroid side effects: bisphosphonates during long-term steroid administration (prevention of osteoporosis), regular monitoring of blood glucose, blood pressure, intraocular pressure, and weight, gastric acid suppressants (prevention of gastric ulcer).

Tertiary prevention (management of chronic complications)

When irreversible organ damage such as pulmonary fibrosis, heart failure, or vision loss has occurred, rehabilitation and supportive therapy aim to maintain function and improve quality of life. This includes pulmonary rehabilitation (respiratory physical therapy, exercise training), optimization of heart failure drug therapy, provision of low-vision aids, and neurorehabilitation (cognitive, speech, and motor therapy). Early detection of relapse and progression and adjustment of treatment through regular follow-up (ACE, calcium, lung function, echocardiography, ophthalmologic examination, neurologic evaluation) are the key to tertiary prevention.


13. References

  1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173. PMID: 10560120

  2. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–1323. DOI: 10.1016/j.hrthm.2014.03.043. PMID: 24819193.

  3. Nunes H, Freynet O, Naggara N, et al. Cardiac sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):428–441. DOI: 10.1055/s-0030-1262213. PMID: 20665396.

  4. Stern BJ, Royal W, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–1553. DOI: 10.1001/jamaneurol.2018.2295. PMID: 30167654.

  5. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–2165. DOI: 10.1056/NEJMra071714. PMID: 18032765.

  6. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155–1167. DOI: 10.1016/S0140-6736(13)60680-7. PMID: 24090799.

  7. Judson MA, Baughman RP, Thompson BW, et al.; ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(3):204–211. PMID: 14620163

  8. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):76–89. PMID: 19382546

  9. Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402. DOI: 10.1016/S2213-2600(18)30064-X. PMID: 29626904.

  10. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–1690. DOI: 10.1016/j.jacc.2005.01.047. PMID: 15893188.